Clinical Trial

Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer

Study acronym: HER-OIC
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The HER-OIC clinical trial is a Phase 1b/2a study investigating a new combination of treatments for patients with HER2-positive gastroesophageal cancer. Standard treatment for localized gastroesophageal cancer usually involves chemotherapy before and after surgery. This study aims to see if adding targeted therapy (zanidatamab) and immunotherapy (tislelizumab) to standard chemotherapy is safe and effectively eliminates the tumor. The goal is to improve the pathological complete response (pCR) rate, which is the percentage of patients who have no visible cancer cells remaining in the tissue removed during surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-12.
Trial Details
NCT Number NCT07477444
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Conditions Gastroesophageal Cancer
Enrollment 29 participants
Start Date 2026-06-01
Primary Completion 2028-06 (estimated)
Study Completion 2033-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-20